U.S. patent application number 14/009218 was filed with the patent office on 2014-02-06 for use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing.
This patent application is currently assigned to L'OREAL. The applicant listed for this patent is Maria Dalko, Sophie Saussay. Invention is credited to Maria Dalko, Sophie Saussay.
Application Number | 20140039064 14/009218 |
Document ID | / |
Family ID | 44548809 |
Filed Date | 2014-02-06 |
United States Patent
Application |
20140039064 |
Kind Code |
A1 |
Dalko; Maria ; et
al. |
February 6, 2014 |
USE OF GINGERONE OR DERIVATIVES THEREOF FOR REDUCING OR DELAYING
THE SIGNS OF SKIN AGEING
Abstract
Use of gingerone or derivatives thereof for reducing or delaying
the signs of skin ageing. The present invention relates to the
cosmetic use of at least one compound of general formula (I): in
which:--R.sub.1 represents a methyl or ethyl radical;--R.sub.2
represents a hydrogen atom or a methyl or ethyl radical;--R.sub.3
represents a linear C.sub.1-C.sub.6 or branched C.sub.3-C.sub.6
alkyl radical, or a linear C.sub.2-C.sub.6 or branched
C.sub.3-C.sub.6 alkenyl radical; and--X represents =O or --OH, as
an agent for reducing and/or delaying the signs of skin ageing.
##STR00001##
Inventors: |
Dalko; Maria; (Versailles,
FR) ; Saussay; Sophie; (Plailly, FR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Dalko; Maria
Saussay; Sophie |
Versailles
Plailly |
|
FR
FR |
|
|
Assignee: |
L'OREAL
Paris
FR
|
Family ID: |
44548809 |
Appl. No.: |
14/009218 |
Filed: |
March 30, 2012 |
PCT Filed: |
March 30, 2012 |
PCT NO: |
PCT/EP2012/055886 |
371 Date: |
October 1, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61472659 |
Apr 7, 2011 |
|
|
|
Current U.S.
Class: |
514/678 |
Current CPC
Class: |
A61K 8/35 20130101; A61Q
19/08 20130101; A61K 8/347 20130101; A61P 17/00 20180101 |
Class at
Publication: |
514/678 |
International
Class: |
A61K 8/35 20060101
A61K008/35; A61Q 19/08 20060101 A61Q019/08 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 1, 2011 |
FR |
1152803 |
Claims
1. A method for reducing signs of skin aging, delaying signs of
skin aging, or both, the method comprising applying a compound of
general formula (I): ##STR00012## wherein: R.sub.1 is a methyl or
ethyl radical; R.sub.2 is a hydrogen atom or a methyl or ethyl
radical; R.sub.3 represents is a linear C.sub.1-C.sub.6 or branched
C.sub.3-C.sub.6 alkyl radical, or a linear C.sub.2-C.sub.6 or
branched C.sub.3-C.sub.6 alkenyl radical; and X is =O or --OH, as
an agent, to the skin.
2. The method according to claim 1, wherein R.sub.3 is a
C.sub.1-C.sub.6 linear alkyl.
3. The method according to claim 1, wherein the compound of general
formula (I), alone or as a mixture, is at least one selected from
the group consisting of: ##STR00013##
4. The method according to claim 1, wherein the compound is
gingerone or ethyl gingerone.
5. The method according to claim 1, for combating signs of
chronobiological ageing of an epidermis, photoinduced ageing of the
epidermis, or both.
6. The method according to claim 1, wherein the signs of skin
ageing are chosen from an appearance of wrinkles and fine lines,
weakening, withering, thinning, dryness, or dull or non-radiant
appearance, complexion, heterogeneous surface of the skin, or any
combination thereof.
7. The method according to claim 1, wherein the compound is
present, in a composition comprising a physiologically acceptable
medium, in a content between 0.1% and 10% by weight relative to a
total weight of the composition.
8. The method according to claim 7, wherein the composition is
suitable for topical application.
Description
[0001] The present invention relates to the field of ageing and of
the signs that are associated therewith, on the skin. It relates in
particular to the adjustment of the equilibrium between the
proliferation and the differentiation of the epidermal cells.
[0002] Women, or even men, currently have a tendency to want to
look young for as long as possible and consequently seek to tone
down the signs of skin ageing, which result in particular in
wrinkles and fine lines, a thinning of the epidermis and/or a
flaccid and withered skin appearance. In this regard, the
advertising and fashion industries mention products for retaining
radiant and wrinkle-free skin, signs of youthful skin, as long as
possible, all the more so since physical appearance has an effect
on the psyche and/or on morale.
[0003] The skin constitutes a physical barrier between the body and
its surroundings. It is constituted of two tissues: the epidermis
and the dermis.
[0004] The dermis provides the epidermis with a solid support. It
is also its nourishing element. It is formed mainly from
fibroblasts and an extracellular matrix, which is itself composed
mainly of collagen, elastin and a substance known as ground
substance, these components being synthesized by the fibroblast.
Leukocytes, mast cells or else tissue macrophages are also found
therein. It also contains blood vessels and nerve fibres.
[0005] The epidermis is a desquamating pluristratified epithelium
that is 100 .mu.m thick on average and is conventionally divided
into a basal layer of keratinocytes that constitutes the germinal
layer of the epidermis, a spinous layer constituted of several
layers of polyhedral cells positioned on the germinal cells, a
granular layer constituted of flattened cells containing distinct
cytoplasmic inclusions, keratohyalin granules, and finally an upper
layer known as the cornified layer (or stratum corneum),
constituted of keratinocytes at the terminal stage of their
differentiation, known as corneocytes. These are mummified
anucleated cells which derive from keratinocytes. The stack of
these corneocytes constitutes the cornified layer that is
responsible, inter alia, for the barrier function of the epidermis,
i.e. it constitutes a barrier against external attacks, especially
chemical, mechanical or infectious attacks and it also makes it
possible to protect the body from water loss.
[0006] Epidermal differentiation follows a process of continuous
and oriented maturation in which the basal keratinocytes transform
while migrating so as to result in the formation of corneocytes,
dead cells that are completely keratinized. This differentiation is
the result of perfectly coordinated phenomena which will result in
the thickness of the epidermis being kept constant and thus ensure
the homeostasis of the epidermis. This goes through a regulation of
the number of cells that enter into the differentiation process and
of the number of cells that desquamate. In the course of the normal
desquamation process, only the most superficial corneocytes detach
from the surface of the epidermis.
[0007] Keratins are insoluble proteins produced by the epithelial
cells in the form of structurally well organized filaments. These
proteins are the main marker of differentiation since throughout
epidermal differentiation, various types of keratin will be more or
less expressed by the keratinocytes.
[0008] Other proteins, associated with keratins, play very
important roles in the skin. Filaggrin (or filagrin), a protein
present in keratohyalin granules, is produced during the final
stages of the differentiation of the epidermis. It is especially
involved in the maturation process of the cornified layer by
enabling type I and type II keratins to be arranged into coils.
This protein thus enables the formation of the cytoplasmic matrix
of the surface corneocytes which in particular gives the skin its
normal thickness, its smooth appearance and its light-reflecting
properties. Furthermore, via its degradation within corneocytes,
filaggrin provides water-soluble substances having a high osmotic
power (natural moisturizing factors or NMFs) that enable a good
hydration of the cornified layer of the skin to be maintained and
thus avoid the feelings of "dry skin". Filaggrin therefore enables
the barrier function of the epidermis to be maintained and makes it
possible to avoid drying out the skin.
[0009] In the course of chronobiological ageing, the thickness of
the epidermis is reduced, maturation of the keratinocytes is
imperfect and keratinization no longer leads to an even and
homogeneous cornified layer being created. It is also known that
prolonged and/or repeated exposures to the sun lead to quite
similar results on the epidermis. This is photoinduced ageing. It
is also known that, at the menopause, skin ageing accelerates, the
thickness of the epidermis decreases, women complain of their skin
tightening and that it takes on the look of "dry skin", or even of
the appearance of xerosis.
[0010] Surprisingly, the inventors have demonstrated that gingerone
and some of the derivatives thereof increased the expression of
filaggrin in the keratinocytes. As filaggrin is a marker of the
differentiation of keratinocytes, gingerone and some of the
derivatives thereof therefore have an effect of stimulating the
differentiation of these cells and thus the maturation of the
cornified layer. They thus enable the skin to retain or regain a
normal thickness, to also have a smooth appearance, i.e without, or
with fewer, wrinkles and fine lines than before their use and a
more radiant, less dull complexion.
[0011] Furthermore, since filaggrin is involved in the skin
hydration process, by increasing the expression of this protein in
keratinocytes, these compounds enable the skin to fully carry out
its barrier function while avoiding, in particular, the drying out
thereof. They therefore make it possible to reestablish or maintain
good hydration of the skin.
[0012] These compounds therefore prove particularly advantageous
for combating the appearance of the signs of skin ageing and for
combating the drying out of the skin, whether or not this is linked
to the ageing thereof.
[0013] Gingerone (INCI name: Zingerone), is a phenolic compound
from the vanilloid family. Its formula and those of several of its
derivatives are given below. Ginger (Zingiber officinale), mango,
cranberry or raspberry may be natural sources of gingerone. Ginger,
and in particular ginger oleoresin, is however the main source
thereof. This molecule is to a large extent responsible for the hot
flavour of ginger.
[0014] Gingerone has already been cited among the ingredients of
topical anti-ageing care compositions but it was used as a blood
circulation "accelerator" (JP 2004323401, JP 2005066831) or as a
hyperemizing agent (EP 1 938 789) or as an antioxidant (EP 1 932
514) or as a caustic, bitter or acid substance (JP 2004210656).
[0015] To the knowledge of the inventors, gingerone and some of the
derivatives thereof have never been described as being
pro-differentiating for keratinocytes and as being able to be used
specifically for treating or delaying the appearance of the signs
of skin ageing.
[0016] One subject of the present invention is thus the use of at
least one compound of general formula (I):
##STR00002##
[0017] in which: [0018] R.sub.1 represents a methyl or ethyl
radical; [0019] R.sub.2 represents a hydrogen atom or a methyl or
ethyl radical; [0020] R.sub.3 represents a linear C.sub.1-C.sub.6
or branched C.sub.3-C.sub.6 alkyl radical, or else a linear
C.sub.2-C.sub.6 or branched C.sub.3-C.sub.6 alkenyl radical; and
[0021] X represents =O or --OH,
[0022] as an agent for reducing and/or delaying the signs of skin
ageing.
[0023] Preferably, these compounds are of general formula (I) in
which: [0024] R.sub.1 represents a methyl or ethyl radical; [0025]
R.sub.2 represents a hydrogen atom or a methyl or ethyl radical;
[0026] R.sub.3 represents a C.sub.1-C.sub.6 linear alkyl; and
[0027] X represents =O or --OH.
[0028] In particular, use will be made of compounds of general
formula (I) in which: [0029] R.sub.1 represents a methyl or ethyl
radical; [0030] R.sub.2 represents a hydrogen atom or a methyl or
ethyl radical; [0031] R.sub.3 represents a C.sub.1-C.sub.6 linear
alkyl; and [0032] X represents =O.
[0033] According to the present invention, the compound of general
formula (I) mentioned above will preferably be chosen, alone or as
a mixture, from the following compounds:
TABLE-US-00001 Number and name of the Formula of the compound
compound Compound 1: Gingerone or Zingerone or vanillylacetone CAS
number: 122-48-5 ##STR00003## Compound 2: 4-(3-ethoxy-
4-hydroxyphenyl)-2- butanone (7Ci) or ethyl gingerone CAS number:
569646-79-3 ##STR00004## Compound 3: 4-(3-ethoxy-
4-hydroxyphenyl)-2- butanol ##STR00005## Compound 4: 1-paradol CAS
number: 53171-99-6 ##STR00006## Compound 5: 4-(3- methoxy-4-
hydroxyphenyl)-3- methylbutane-2-one CAS number: 83092-97-1
##STR00007## Compound 6: 3-paradol CAS number: 53172-01-3
##STR00008## Compound 7: 1-(4- hydroxy-3-methoxy-
phenyl)nonan-3-one CAS number: 53172-03-5 ##STR00009##
[0034] The preferred compound will be chosen from gingerone (or
zingerone) or ethyl gingerone. The gingerone may be, for example,
supplied by the company Aldrich. Most preferred is ethyl
gingerone.
[0035] Compounds 2 and 7 may be, for example, supplied by the
company SinoChemExper.
[0036] The compounds of general formula (I), as targeted above,
could be used in the form of a more or less purified molecule of
natural or synthetic origin. They will preferably be of natural
origin. In particular, some of these compounds could be provided in
the form of plant extracts containing them, and especially in the
form of an extract of ginger, of mango, of cranberry and/or of
raspberry.
[0037] Such compounds may be synthesized via synthesis pathways
known in the prior art. They may in particular be prepared from
commercial vanillin or ethyl vanillin. Gingerone, for example,
could be obtained via the condensation of vanillin by acetone,
followed by a hydrogenation.
[0038] The expression "cutaneous signs of ageing" is understood to
mean any modification in the external appearance of the skin due to
ageing, whether chronobiological and/or photoinduced, such as, for
example, wrinkles and fine lines, withered skin, flaccid skin,
slack skin, thinned skin, dry skin, dull skin that lacks radiance,
heterogeneity of the complexion and of the surface of the skin. The
signs of chronobiological or chronological ageing (also known as
chronoageing) correspond to internal degradations of the skin due
to the intrinsic ageing of the individuals. The signs of
photoinduced ageing (or photoageing) correspond to internal
degradations of the skin following exposure to ultraviolet
radiation.
[0039] The term "skin" is understood to mean, for the purposes of
the invention, the whole of the body covering, and in particular
the skin, mucous membranes and scalp.
[0040] The reduction of the signs of skin ageing and/or the
delaying of their appearance, via the use of the compounds
according to the present invention, takes place in particular owing
to the increase or improvement in the differentiation of the
epidermal cells and/or the increase or stimulation in particular of
the expression of filaggrin in the epidermal keratinocytes.
[0041] Preferably, the compositions used according to the invention
are cosmetic compositions, i.e. they are intended to improve the
aesthetic appearance of the individual.
[0042] The use according to the present invention is especially
effective for combating the signs, in particular aesthetic signs,
of chronobiological and/or photoinduced ageing of the epidermis.
Through the present invention, combating the signs of
chronobiological ageing of the skin will preferably be
targeted.
[0043] The present invention is thus effective in any person
regardless of their age. When combating the signs of
chronobiological ageing, the individuals preferably targeted will
be individuals of more than 30 years old, preferably more than 40
years old.
[0044] The signs of skin ageing are preferably chosen from the
appearance of wrinkles and fine lines and/or the weakening and/or
the slackening and/or the withering and/or the thinning and/or the
dryness and/or the dull and/or non-radiant appearance and/or the
complexion and/or the heterogeneous surface of the skin.
[0045] Through the present invention, skin having a more youthful
appearance and better hydrated skin are therefore obtained.
[0046] The compound of general formula (I) as targeted above is
present, in a composition comprising a physiologically acceptable
medium, in a content between 0.1% and 10% by weight relative to the
total weight of said composition.
[0047] A "physiologically acceptable medium" is, according to the
invention, a cosmetically acceptable medium that is compatible with
the skin, the mucous membranes, the nails and/or the hair.
[0048] The expression "cosmetically acceptable medium" is
understood to mean a medium that has no unpleasant appearance, and
that does not cause the user any unacceptable stinging, tautness or
redness.
[0049] The physiologically acceptable medium will be adapted to the
nature of the support onto which the composition is to be applied,
and also to the form in which the composition is intended to be
packaged, in particular solid or fluid at room temperature and
atmospheric pressure.
[0050] The composition is preferably suitable for topical
application.
[0051] For an administration via topical application to the skin
and/or the mucous membranes, the composition according to the
invention of course comprises a cosmetically acceptable support,
i.e. a support that is compatible with the skin, the mucous
membranes, the nails, the hair, and may be in any galenic form
normally used for a topical application, in particular in the form
of an aqueous, aqueous-alcoholic or oily solution, an oil-in-water
or water-in-oil or multiple emulsion, an aqueous or oily gel, a
liquid, pasty or solid anhydrous product, a suspension or a
dispersion; for example a dispersion of oil in an aqueous phase
using spherules, it being possible for these spherules to be
polymeric nanoparticles, such as nanospheres and nanocapsules, or
better still lipid vesicles of ionic and/or nonionic type.
[0052] This composition may be more or less fluid and may have the
appearance of a white or coloured cream, an ointment, a milk, a
lotion, a serum, a paste or a foam. It can optionally be applied to
the skin in aerosol form. It can also be in solid form, for example
in the form of a stick. It can be used as a care product or as a
cleansing product or as a makeup product.
[0053] In a known manner, the composition of the invention may
contain adjuvants that are common in the cosmetic and
dermatological fields, such as hydrophilic or lipophilic gelling
agents, hydrophilic or lipophilic active agents, preserving agents,
antioxidants, solvents, fragrances, fillers, screening agents,
pigments, chelating agents, odour absorbers and colorants. The
amounts of these various adjuvants are those conventionally used in
the fields under consideration, for example from 0.01% to 20% of
the total weight of the composition. Depending on their nature,
these adjuvants may be introduced into the fatty phase, into the
aqueous phase, into the lipid vesicles and/or into the
nanoparticles.
[0054] When the composition of the invention is an emulsion, the
proportion of the fatty phase may range from 5% to 80% by weight
and preferably from 5% to 50% of the total weight of the
composition. The oils, emulsifiers and coemulsifiers used in the
composition in emulsion form are chosen from those conventionally
used in the field under consideration. The emulsifier and the
coemulsifier are present in the composition in a proportion ranging
from 0.3% to 30% by weight and preferably from 0.5% to 20% of the
total weight of the composition.
[0055] As oils that can be used in the invention, mention may be
made of mineral oils, oils of plant origin (apricot oil, sunflower
oil), oils of animal origin, synthetic oils, silicone-based oils
and fluorinated oils (perfluoropolyethers). As fatty substances,
use may also be made of fatty alcohols (cetyl alcohol), fatty acids
and waxes (beeswax).
[0056] As emulsifiers and coemulsifiers that can be used in the
invention, mention may for example be made of polyethylene glycol
fatty acid esters such as PEG-40 stearate and PEG-100 stearate, and
polyol fatty acid esters such as glyceryl stearate and sorbitan
tristearate.
[0057] As hydrophilic gelling agents, mention may particularly be
made of carboxyvinyl polymers (carbomer), acrylic copolymers such
as acrylate/alkyl acrylate copolymers, polyacrylamides,
polysaccharides, natural gums and clays, and, as lipophilic gelling
agents, mention may be made of modified clays such as bentones,
metal salts of fatty acids, hydrophobic silica and
polyethylenes.
[0058] According to one advantageous embodiment, the compositions
according to the invention will contain at least one other active
agent chosen from anti-UV screening agents, moisturizers,
depigmenting agents, anti-glycation agents, NO-synthase inhibitors,
agents for stimulating the synthesis of dermal or epidermal
macromolecules and/or for preventing their degradation, agents for
stimulating fibroblast or keratinocyte proliferation, myorelaxants
or dermo-decontracting agents, tensioning agents, agents for
combating pollution or free-radical scavengers, calmatives and
active agents that act on the energy metabolism of cells.
[0059] The amount of these additional active agents could vary to a
large extent and will be for example from 10.sup.-6% to 20% by
weight, especially from 0.001% to 10% by weight relative to the
total weight of the composition.
[0060] The agents for stimulating fibroblast proliferation that may
be used in the composition according to the invention may be
chosen, for example, from plant proteins or polypeptides, extracted
especially from soybean (for example a soybean extract sold by the
company LSN under the name Eleseryl SH-VEG 8.RTM. or sold by the
company Silab under the trade name Raffermine.RTM.); and plant
hormones such as gibberellins and cytokinins.
[0061] The agents for stimulating keratinocyte proliferation that
can be used in the composition according to the invention
especially comprise retinoids such as retinol and esters thereof,
including retinyl palmitate; adenosine, cinnamic acid and
derivatives thereof, lycopene and derivatives thereof;
phloroglucinol; the walnut meal extracts sold by the company
Gattefosse; and the extracts of Solanum tuberosum sold by the
company Sederma.
[0062] Preferably, for the implementation of the invention, the
compound of general formula (I) as described above, and/or the
composition containing it, will be applied to the part of the skin
to be treated, in particular to the face, the neck or the hands,
daily or several times daily; the application will be repeated
every day for a variable period depending on the effects desired,
generally from 3 to 6 weeks, but which could be extended or carried
out continuously.
[0063] The compound of general formula (I) as described above or
the composition containing it will preferably be applied to the
areas of skin affected by the signs of ageing that it is desired to
combat.
[0064] For an oral administration, the composition of the invention
may be in any suitable form, particularly in the form of a solution
to be taken orally, a tablet, a gel capsule, a capsule or
alternatively a nutritional food or a nutritional supplement.
[0065] Said composition additionally comprises at least one
appropriate excipient suitable for oral administration.
[0066] In the case of active agents or of compositions according to
the invention being taken orally, the oral administration may be
daily or several times daily, for example morning and evening. It
could be continued for several weeks and/or several months,
depending on the effects desired.
[0067] The examples given below are presented as non-limiting
illustrations of the invention.
EXAMPLES
[0068] 1. Method of Preparing a Compound According to the
Invention
[0069] The method of preparing these compounds of general formula
(I) may be, for example, the following:
##STR00010##
[0070] The method of preparing compound 3 comprises a supplementary
reduction step:
##STR00011##
[0071] The compounds according to the invention are prepared here
either from commercial vanillin (CAS: 121-33-5), or from commercial
ethyl vanillin (CAS: 121-32-4).
[0072] 2. Demonstration of the Activity of a Compound According to
the Invention
[0073] The in vitro effect of gingerone (compound 1, the chemical
formula of which is given above) on keratinocyte differentiation is
studied. The expression and the location of the marker of filaggrin
differentiation are especially studied in keratinocytes in culture
which thus makes it possible to evaluate the capacity of this
compound to increase the differentiation of these cells.
[0074] Procedure:
[0075] Normal human keratinocytes (NHEKs) were cultured at
37.degree. C. and 5% CO.sub.2 for 24 h in a complete SFM medium
until moderate confluence was obtained. A complete SFM medium is an
SFM culture medium supplemented with pituitary extract (25
.mu.g/ml), EGF (0.25 ng/ml) and gentamicin (25 .mu.g/ml).
[0076] At the end of the incubation, the medium was withdrawn and
replaced with culture medium that did or did not contain various
concentrations of the test product or reference molecules. Calcium
chloride and retinoic acid, which are known respectively as a
stimulator and as an inhibitor of the keratinocyte differentiation,
were used as reference molecules for this test. The keratinocytes
were then incubated for 144 hours. The treatments were carried out
in triplicate (n=3).
[0077] At the end of the incubation, the culture medium was removed
and the cells were rinced, fixed, permeabilized then labelled with
the primary antibody targeted against the filaggrin protein of
interest (in situ immunolabelling). This antibody was then revealed
by a secondary antibody coupled to a fluorochrome (GAM-Alexa 488).
At the same time, the nuclei of the cells were stained with Hoechst
33258 (bisbenzimide).
[0078] Image acquisition was carried out using an INCell
Analyzer.TM. 1000 machine. The labels were quantified by measuring
the fluorescence intensity of the proteins relative to the number
of nuclei identified by the Hoechst product.
[0079] Results
[0080] The results are given in Table 1 below:
TABLE-US-00002 TABLE 1 % relative to Treatment the control Control
complete SFM 100 medium CaCl.sub.2 1.5 mM 158** Retinoic acid
10.sup.-7M 3** Gingerone 2 .mu.g/ml 133* 20 .mu.g/ml 151*
Significant difference relative to the control medium (*p < 0.05
and **p < 0.01).
[0081] Under the experimental conditions of this study, the
treatment with calcium chloride, pro-differentiating reference
molecule, substantially increases the expression of filaggrin by
the keratinocytes (+58% relative to the control). [0082] Under the
experimental conditions of this study, the treatment with retinoic
acid, anti-differentiating reference molecule, substantially
decreases the expression of filaggrin by the keratinocytes (-97%
relative to the control). [0083] The treatment with gingerone at 2
.mu.g/ml and 20 .mu.g/ml significantly and dose-dependently
stimulates the expression of filaggrin (+33% and +51% respectively
relative to the control) by the keratinocytes.
[0084] Conclusion
[0085] Gingerone significantly and dose-dependently increases the
expression of the filaggrin protein in normal human epidermal
keratinocytes.
[0086] The results obtained thus translate into an increase in
epidermal differentiation. Gingerone therefore has a
pro-differentiating effect on normal human keratinocytes and
therefore can thus reduce and/or delay the signs of skin
ageing.
[0087] 3. Composition Examples
[0088] 3.1. Lotion
[0089] A lotion is prepared, comprising (% by weight):
TABLE-US-00003 compound tested in Example 1 (gingerone) 0.75%
glycerol 2% ethyl alcohol 20% demineralized water qs 100%
[0090] The composition according to the invention applied daily to
the face makes it possible to combat the signs of skin ageing.
[0091] 3.2. Facial Gel
[0092] A facial gel is prepared, comprising (% by weight):
TABLE-US-00004 glyceryl polyacrylate (Norgel) 30%
polyacrylamide/C13-14 isoparaffin/laureth-7 (Sepigel 305) 2%
silicone oil 10% compound 1 (gingerone) 5% water qs 100%
[0093] The composition according to the invention applied daily to
the face makes it possible to combat the signs of skin ageing.
* * * * *